Navigation Links
Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
Date:6/9/2008

than predicted.

In the trial, investigators said that they were "more aggressive" with AVANDIA and other medications in the intensive arm to achieve and maintain tight glycemic targets. The investigators found that in VADT, there were no increased deaths associated with any of the medications used in the trial, including AVANDIA.

Findings from ACCORD

ACCORD, which investigated whether or not intensive blood control would reduce CV events in patients with type 2 diabetes who had either established cardiovascular disease or additional CV risk factors, was presented at a press conference during the ADA Scientific Sessions and published simultaneously in the New England Journal of Medicine. The study had a mean follow-up of 3.5 years. In total, 7,623 patients enrolled in the ACCORD trial took AVANDIA, representing more than 19,200 patient years of experience with the medication.

The investigators found that, as compared with standard therapy, the use of intensive therapy to reach the study's A1C goal for 3.5 years did not significantly reduce major CV events. Although they found an increase in CV deaths among these high-risk patients who were in the intensive arm, the death rates from ACCORD were substantially lower than investigators predicted at the outset of the trial.

In their analysis, the investigators noted that "preliminary nonprespecified exploratory analyses of episodes of severe hypoglycemia after randomization and differences in the use of drugs (including rosiglitazone), weight change, and other factors did not identify an explanation for the mortality finding."

Additionally, an accompanying editorial in the New England Journal of Medicine states, " ... the ACCORD trial investigators concluded that patients in the standard-control group and those in the intensive-control group had similar risks and rates of death, whether or not they were prescribed rosiglitazone."

Other Studies of AVANDIA

In an integr
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
2. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
3. Video: New Research Discovers Independent Brain Networks Control Human Walking
4. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
5. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
8. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
9. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
10. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
11. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Quietly, ... of experience, the domestic pharmaceutical industry is strong, with ... products to high international standards. One place ... is in sub-Saharan Africa: Morocco has quietly become the ... South Africa . Indeed, Moroccan pharma companies ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 /PRNewswire/ ... Co., Ltd. (Headquarters: Tokyo , President ... Therapeutics, Inc. (Headquarters: San Diego, California ... "NASDAQ: HALO") have signed a clinical collaboration agreement to ... "eribulin") in combination with Halozyme,s investigational drug PEGPH20 (PEGylated ...
(Date:7/31/2015)... Magnaquest, a leading Subscription ... cloud computing operators has signed a Proof of ... Internet of Things (IoT) related initiative. The PoC ... model.      (Logo: http://photos.prnewswire.com/prnh/20140807/700645 ) ... business innovations to make healthcare services more accessible ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... to Destroy,Lung Tumors, WASHINGTON, March 17 ... that "cooks" and kills lung cancer,tumors with ... primary or,metastatic inoperable lung tumors, according to ... Interventional Radiology,s 33rd Annual Scientific Meeting.,Of the ...
... Therapeutics,(Amex: CXM ) and its subsidiary, Tissue ... MATRIX clinical study has been the focus of ... television news,features in Florida, Pennsylvania, Arizona and Southern ... efficacy of Excellarate(TM) for,the potential treatment of non-healing ...
Cached Medicine Technology:Treatment Gives Lung Cancer Patients With Inoperable Tumors Two Years or More 2Treatment Gives Lung Cancer Patients With Inoperable Tumors Two Years or More 3Treatment Gives Lung Cancer Patients With Inoperable Tumors Two Years or More 4Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S. 2Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S. 3Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S. 4Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S. 5Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S. 6
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on NewsWatch ... coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the host ... users to clarify, edit and delete any message including ones already sent. , While ...
(Date:7/31/2015)... ... , ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened ... 20-21 July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and ... Advisor, Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... new store run by GoodThreads. The store can be accessed by visiting ... many of which are customizable. The best part: whenever a product is purchased, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin and blogs ... social media profiles to better connect with the public. The agency website at ... share insights and opinions. The Rally Insurance Group, Inc.’s pledge to provide effortless ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article ... see if they could reach a consensus on the steps that need to be ... the group reached 90 percent consensus on a series of steps that each surgeon ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... , THURSDAY, May 3 (HealthDay News) -- A ... with schizophrenia, cutting patients, risk of relapse by 60 percent. ... also found that schizophrenia patients who take antipsychotics are much ... and have a better quality of life than patients who ...
... jogging increases the life expectancy of men by 6.2 years ... the Copenhagen City Heart study presented at the EuroPRevent2012 meeting. ... hazardous, Peter Schnohr told delegates that the study,s most recent ... hours of jogging per week at a "slow or ...
... eating is motivated by pleasure, rather than hunger, endogenous rewarding ... to a recent study accepted for publication in The Endocrine ... The phenomenon ultimately affects body mass and may be a ... refers to the desire to eat for pleasure, and to ...
... New York, NYThe United States spends more on health care ... superior" care, according to a new study from The Commonwealth ... on health care services, while other countries in the study ... and Switzerland) as much. While the U.S. performs well on ...
... 2D mammography screening results in a 40% reduction in ... a new study shows., The study, conducted at Yale ... 7,578 screening mammograms, found that the recall rate was ... It was 11.1% for 2D screening mammography alone, ...
... with benign breast biopsies do not need follow-up at six months; ... shows. , The study, conducted at Moffitt ... and 24 months. No cancer was found in these patients ... the authors of the study. "Of the 197 follow-up examinations ...
Cached Medicine News:Health News:Antipsychotics Do Help Many With Schizophrenia, Study Finds 2Health News:Antipsychotics Do Help Many With Schizophrenia, Study Finds 3Health News:Regular jogging shows dramatic increase in life expectancy 2Health News:Regular jogging shows dramatic increase in life expectancy 3Health News:Pleasure eating triggers body's reward system and may stimulate overeating 2Health News:US spends far more for health care than 12 industrialized nations, but quality varies 2Health News:US spends far more for health care than 12 industrialized nations, but quality varies 3Health News:US spends far more for health care than 12 industrialized nations, but quality varies 4Health News:Digital breast tomosynthesis cuts recall rates by 40 percent 2
... Drawing on over 20 years of ... AquilionTM 16 is at the forefront of ... ability to acquire volumetric data at high ... was created based on extensive clinical experience ...
... IDT 16 is Philips premium 16-slice CT scanner. ... performed to automatically delivering high quality, advanced results, ... in a platform that has been the most ... do comprehensive organ assessment literally within seconds, and ...
... Instruments are designed to facilitate disc removal, ... graft during interbody fusion. The TLIF instruments ... use during TLIF, for which they were ... used very effectively in PLIF and ALIF. ...
... insertion assembly incorporates slotted guides for ... The PathFinder MIS System uses an ... screw insertion assembly incorporates crescent-shaped slotted ... evolutionary Pathfinder MIS pedicle screw system ...
Medicine Products: